Search Result

Results for "

CB1-IN-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cannabinoid Receptor (16) Isotope-Labeled Compounds (2) Reference Standards (1)
By Research Areas:	Cancer (2) Metabolic Disease (4) Neurological Disease (11)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Dan family AIM2 NEKs CD44

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117754

PSB-SB1202	Cannabinoid Receptor	Neurological Disease
PSB-SB1202 (Compound 21a) is a phenyl coumarin compound. PSB-SB1202 is a *CB1/CB2* agonist with EC₅₀ values of 56 and 14 nM, and K_i values of 32 and 49 nM, respectively .

HY-100488

Bay 59-3074	Cannabinoid Receptor	Cancer
Bay 59-3074 is a selective cannabinoid CB₁/CB₂ receptor partial agonist with K_i values of 48.3 and 45.5 nM at human CB₁ and CB₂ receptors, respectively. Bay 59-3074 has analgesic properties .

HY-119104

AZD1940	Cannabinoid Receptor	Neurological Disease
AZD1940 is an orally active, high affinity *cannabinoid CB1/CB2* receptor agonist with pK_i values of 7.93 and 9.06 for human CB1R and CB2R**, respectively. AZD1940 shows a robust analgesia action .

HY-150029

CB1/2 agonist 3	Cannabinoid Receptor	Neurological Disease
CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a *CB1/CB2* (cannabinoid receptor) competitive agonist. CB1/2 agonist 3 acts on hCB1 and hCB2 with K_i values of 5.9 nM and 3.5 nM, respectively .

HY-130311

2-Linoleoyl glycerol 2-MonolINoleIN; 2-MonolINoleoylglycerol	Cannabinoid Receptor	Neurological Disease
2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .

HY-124089

Eicosapentaenoyl ethanolamide	Cannabinoid Receptor	Metabolic Disease
Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is *cannabinoid CB1/CB2* receptor** agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant .

HY-147821

*CB1-IN-2*	Cannabinoid Receptor	Metabolic Disease
CB1-IN-2 (Compound 4g) is a selective CB₁ inhibitor with an IC₅₀ of 0.644 μM. CB1-IN-2 can penetrates BBB and might cause CNS side effect similar with Rimonabant .

HY-110048

O-2545 hydrochloride	Cannabinoid Receptor	Neurological Disease
O-2545 hydrochloride is a highly potent, water-soluble *CB1/CB2* receptor agonist (with K_i values of 1.5 and 0.32 nM for CB1 and CB2 respectively), can be used for epilepsy, pain, multiple sclerosis research .

HY-119744

BAY 38-7271	Cannabinoid Receptor	Neurological Disease
BAY 38-7271 is selective and highly potent and cannabinoid CB₁/CB₂ receptor agonist, with K_is of 1.85 nM and 5.96 nM for recombinant human CB₁ receptor and CB₂ receptor, respectively. BAY 38-7271 has strong neuroprotective properties .

HY-164913

PSB-SB-1203	Cannabinoid Receptor	Metabolic Disease Cancer
PSB-SB-1203 (Compound 25b) is a dual *CB1/CB2* ligand that blocks CB1 but activates CB2 receptors (CB1 K_i 0.244 μM; CB2 K_i 0.210 μM, EC₅₀ 0.054 μM). PSB-SB-1203 is promising for research of obesity and cancers .

HY-124089S

Eicosapentaenoyl ethanolamide-d4	Isotope-Labeled Compounds Cannabinoid Receptor	Metabolic Disease
Eicosapentaenoyl ethanolamide-d₄ is the deuterium labeled Eicosapentaenoyl ethanolamide. Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant .

HY-116649

*CB1 antagonist 2* AM4113	Cannabinoid Receptor	Neurological Disease
CB1 antagonist 2 is caimabinoid 1 (CB1) antagonist extracted from patent WO2016184310A1, compound 3, inhibits CB1 in vivo with an IC₅₀ of 25.5 nM .

HY-W770198

2-Linoleoyl glycerol-d5 2-MonolINoleIN-d₅; 2-MonolINoleoylglycerol-d₅	Isotope-Labeled Compounds Cannabinoid Receptor	Neurological Disease
2-Linoleoyl glycerol-d₅ (2-Monolinolein-d₅; 2-Monolinoleoylglycerol-d₅) is the deuterium labeled 2-Linoleoyl glycerol (HY-130311). 2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .

HY-W013788

2-Palmitoylglycerol 2-Palm-Gl	Cannabinoid Receptor	Neurological Disease
2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .

HY-173543

MDA-19 N-(5-hydroxyhexyl)	Cannabinoid Receptor	Neurological Disease
MDA-19 N-(5-hydroxyhexyl) is a cannabinoid receptor modulator targeting CB1R/CB2R. MDA-19 N-(5-hydroxyhexyl) is used to study neurological diseases, cancer, and pain regulation .

HY-W013788R

2-Palmitoylglycerol (Standard) 2-Palm-Gl (Standard)	Reference Standards Cannabinoid Receptor	Neurological Disease
2-Palmitoylglycerol (Standard) is the analytical standard of 2-Palmitoylglycerol. This product is intended for research and analytical applications. 2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W013788

2-Palmitoylglycerol 2-Palm-Gl	Structural Classification Natural Products Microorganisms Source classification Endogenous metabolite	Cannabinoid Receptor
2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .

HY-W013788R

2-Palmitoylglycerol (Standard) 2-Palm-Gl (Standard)	Structural Classification Natural Products Microorganisms Source classification Endogenous metabolite	Reference Standards Cannabinoid Receptor
2-Palmitoylglycerol (Standard) is the analytical standard of 2-Palmitoylglycerol. This product is intended for research and analytical applications. 2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .

Cat. No.	Product Name	Chemical Structure

HY-124089S

Eicosapentaenoyl ethanolamide-d4
Eicosapentaenoyl ethanolamide-d₄ is the deuterium labeled Eicosapentaenoyl ethanolamide. Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant .

Eicosapentaenoyl ethanolamide-d4

Eicosapentaenoyl ethanolamide-d₄ is the deuterium labeled Eicosapentaenoyl ethanolamide. Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant .

HY-W770198

2-Linoleoyl glycerol-d5
2-Linoleoyl glycerol-d₅ (2-Monolinolein-d₅; 2-Monolinoleoylglycerol-d₅) is the deuterium labeled 2-Linoleoyl glycerol (HY-130311). 2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .

2-Linoleoyl glycerol-d5

2-Linoleoyl glycerol-d₅ (2-Monolinolein-d₅; 2-Monolinoleoylglycerol-d₅) is the deuterium labeled 2-Linoleoyl glycerol (HY-130311). 2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks